About Contact Us Careers

Diverticulitis Drugs Market Size & Share, by Drug Type {Antibiotics (Metronidazole, Amoxicillin, Moxifloxacin), Dietary Fiber}; Route of Administration (Oral, Intravenous); Distribution Channel (Online, Offline); End-user (Specialty Clinics, Hospitals, Research Centers) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2025-2037

  • Report ID: 3054
  • Published Date: Dec 24, 2024
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2025-2037

Diverticulitis Drugs Market size is set to expand at significant growth rate during the forecast period i.e., between 2025-2037.

This growth can be attributed to the growing prevalence of obesity, rising old age population, and the inclination of youth towards an unhealthy lifestyle. Moreover, eating excessive red meat, and lack of fiber in diet can also lead to diverticulitis. According to a report by the World Health Organization, more than 2 billion people in the world do not have access to a balanced diet. In another report of the WHO, it is stated that around 1.9 billion adults were overweight and 650 million were obese, in the year 2016. In fact, at present, there are more overweight individuals than underweight, globally. This is estimated to elevate the prevalence of diverticulitis, which in turn, is estimated to boost the market growth. Additionally, factors such as government initiatives and support to treat the disease, rising demand for advanced treatment options, and growing market players offering newer products, are anticipated to drive the growth of the market over the coming years.

Diverticulitis-Drugs-Market-Size
Discover Market Trends & Growth Opportunities: Request Free Sample PDF

Growth Drivers

  • Increasing Trend of Sedentary Lifestyle and Unhealthy Diet
  • Increasing Global Geriatric Population

Restraints

  • Lack of Awareness among People Regarding the Disease
  • Stringent Regulations of the Government Regarding the Approval of Medicines

Access Detailed Forecasts & Data-Driven Insights: Request Free Sample PDF

Diverticulitis Drugs Segmentation

The market is segmented by end-user into specialty clinics, hospitals, research centers, and others. Among these, the hospitals segment is anticipated to hold the largest market share over the forecast period on the back of symptoms and complications associated with the disease. Its symptoms include cramps on the left side of the abdomen which goes away after passing gas or stool, abdominal pain, fever, diarrhea, bloating, bleeding from rectum, bright red blood in stool, and others, which often need immediate attention from medical staff.

Our in-depth analysis of the global market includes the following segments:

           By Drug Type
  • Antibiotics
    • Metronidazole
    • Amoxicillin
    • Moxifloxacin
    • Others
  • Dietary Fiber
  • Others

             By Route of Administration
  • Oral
  • Injection

 

 

           By Distribution Channel
  • Online
  • Offline

           By End-User
  • Specialty Clinics
  • Hospitals
  • Research Centers
  • Others
 
Vishnu Nair
Vishnu Nair
Head - Global Business Development

Customize this report to your requirements — connect with our consultant for personalized insights and options.

Diverticulitis Drugs Industry - Regional Synopsis

On the basis of regional analysis, the diverticulitis drugs market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America, and Middle East & Africa region.

North America industry is predicted to dominate majority revenue share by 2037, on account of rising obese population, and availability of advanced treatment options. Additionally, the growing cases of various gastrointestinal diseases, including diverticulitis, is estimated to boost the market growth. According to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), in the United States, about 58% of the individuals above 60 years of age have diverticulosis and about 5% of people with diverticulosis tends to develop diverticulitis. According to another report by the NIDDK, around 200,000 individuals are hospitalized for diverticulitis each year in the United States.

The market in the Asia Pacific is anticipated to grow at the highest CAGR over the forecast period owing to the growing number of patients, rising awareness among the individuals regarding health, availability of new treatment methods, improvement in the standard of living, and rapidly improving health care infrastructure.

Diverticulitis-Drugs-Market-Share
Get Strategic Analysis by Region Now: Request Free Sample PDF

Companies Dominating the Diverticulitis Drugs Landscape

    • Emmaus Life Sciences, Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Synergy Pharma
    • Abbott Laboratories
    • GlaxoSmithKline plc
    •  Ardelyx, Inc.
    • Gilead Sciences, Inc.
    • Trumac Healthcare
    • Pfizer Inc.
    • Hikma Pharmaceuticals PLC
    • Takeda Pharmaceutical Company Limited

Recent Developments

  • January 29, 2020: Emmaus Life Sciences, Inc. has announced the preliminary results observed in the first patient in the company’s phase 1 study of diverticulosis treatment. The results were satisfactory and the company intends to continue the research and development process for novel drugs to treat diverticulitis
  • May 28, 2020: Hikma Pharmaceuticals PLC launched Dicyclomine Hydrochloride Oral Solution for the treatment of various inflammatory bowel diseases, including diverticulosis.
  • Report ID: 3054
  • Published Date: Dec 24, 2024
  • Report Format: PDF, PPT
  • Explore a preview of key market trends and insights
  • Review sample data tables and segment breakdowns
  • Experience the quality of our visual data representations
  • Evaluate our report structure and research methodology
  • Get a glimpse of competitive landscape analysis
  • Understand how regional forecasts are presented
  • Assess the depth of company profiling and benchmarking
  • Preview how actionable insights can support your strategy

Explore real data and analysis

Download Free Sample Report

Frequently Asked Questions (FAQ)

Diverticulitis Drugs Market size is set to expand at significant growth rate during the forecast period i.e., between 2025-2037.

Growing prevalence of gastrointestinal problems backed by unhealthy diet, lifestyle diseases, and obesity, will propel the market growth.

North America industry is predicted to dominate majority revenue share by 2037, on account of rising obese population, and availability of advanced treatment options.

The major players in the market are Abbott Laboratories, Pfizer Inc., GlaxoSmithKline plc, Ardelyx, Inc., Gilead Sciences, Inc., Trumac Healthcare, Hikma Pharmaceuticals PLC, Takeda Pharmaceutical Company Limited and others.

Diverticulitis Drugs Market Report Scope

GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

Connect with our Expert

Radhika Pawar
Radhika Pawar
Senior Research Analyst
Get a Free Sample

See how top U.S. companies are managing market uncertainty — get your free sample with trends, challenges, macroeconomic factors, charts, forecasts, and more.

Inquiry Before Buying Request Free Sample PDF

Copyright @ 2025 Research Nester. All Rights Reserved.

footer-bottom-logos